Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3356-3361

  Snoeck, R ^a   Holy A ^a   Dewolf Peeters, C ^a   Van Den Oord, J ^a   De Clercq, E ^a   Andrei, G ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (PHOSPHONOMETHOXY)ETHYL] 2,4 DIAMINOPYRIMIDINE; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]CYTOSINE; 6 [2 (PHOSPHONOMETHOXY)ETHOXY] 2,4 DIAMINOPYRIMIDINE; 9 [2 (DIISOOCTYLPHOSPHONYLMETHOXY)ETHYL] 2 AMINO 6 CYCLOPROPYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 4 PROPARGYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 (N METHYL N ETHYL)AMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 ALLYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 CHLOROPURINE HYDROBROMIDE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 CYCLOPENTYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 CYCLOPROPYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 DIMETHYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 METHYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 N BUTYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO N6 (PIPERIDIN 1 YL)PURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 8 AZAGUANINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]ADENINE DIISOOCTYL ESTER; 9 [2 (PHOSPHONOMETHOXY)ETHYL]GUANINE; 9 [2 (PHOSPHONOMETHOXY)PROPYL] 2 AMINO 6 CYCLOPROPYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)PROPYL] 6 DIMETHYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)PROPYL]GUANINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 3 DEAZAADENINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 8 AZAADENINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]ADENINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]GUANINE; ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVE; ADEFOVIR; ISOPROPYL 9 [2 (PHOSPHONOMETHOXY)ETHYL]GUANINE; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; MEMBRANE RECONSTITUTION; NEWBORN; PRIORITY JOURNAL; RETINITIS; VACCINIA VIRUS; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; CELL SURVIVAL; EPITHELIAL CELLS; HUMANS; KERATINOCYTES; MODELS, THEORETICAL; MOLECULAR WEIGHT; NUCLEOSIDES; ORGAN CULTURE TECHNIQUES; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINIA; VACCINIA VIRUS;

EID: 0036840576     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3356-3361.2002     Document Type: Article

References (34)

1. Awan, A. R., and H. J. Field. 1993. Effects of phosphonylmethoxyalkyl derivatives studied with a murine model for abortion induced by equine herpesvirus 1. Antimicrob. Agents Chemother. 37:2478-2482.
2. Banker, A. S., E. De Clercq, I. Taskintuna, K. S. Keefe, G. Bergeron-Lynn, and W. R. Freeman. 1998. Influence of intravitreal injections of HPMPC and related nucleoside analogues on intraocular pressure in guinea pig eyes. Investig. Ophthalmol. Vis. Sci. 39:1233-1242.
3. Berche, P. 2001. The threat of smallpox and bioterrorism. Trends Microbiol. 9:15-18.
4. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
5. Breman, J. G., and D. A. Henderson. 1998. Poxvirus dilemmas - monkeypox, smallpox, and biologic terrorism. N. Engl. J. Med. 339:556-559.
6. Calista, D. 2000. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J. Eur. Acad. Dermatol. Venereol. 14:484-488.
7. Davies, E. G., A. Thrasher, K. Lacey, and J. Harper. 1999. Topical cidofovir for severe molluscum contagiosum. Lancet 353:2042.
8. De Clercq, E., A. Holý, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464-467.
9. De Clercq, E., T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holý. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir. Res. 8:261-272.
10. De Clercq, E., A. Holý, and I. Rosenberg. 1989. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob. Agents Chemother. 33:185-191.
11. De Clercq, E. 1997. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 10:674-693.
12. De Clercq, E. 2001. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:382-397.
13. Geerinck K., G. Lukito, R. Snoeck, R. De Vos, E. De Clercq, Y. Vanrenterghem, H. Degreef, and B. Maes. 2001. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64:543-549.
14. Henderson, D. A. 1998. Bioterrorism as a public health threat. Emerg. Infect. Dis. 4:488-492.
15. Henderson, D. A., T. V. Inglesby, J. G. Bartlett, M. S. Ascher, E. Eitzen, P. B. Jahrling, J. Hauer, M. Layton, J. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. Perl, P. K. Russel, K. Tonat, et al. 1999. Smallpox as a biological weapon: medical and public health management. JAMA 9:2127-2137.
16. Heymann, D. L., M. Szczeniowski, and K. Esteves. 1998. Re-emergence of monkeypox in Africa: a review of the past six years. Br. Med. Bull. 54:693-702.
17. Holý, A., I. Votruba, A. Merta, J. Cerny, J. Vesely, J. Vlach, K. Sediva, I. Rosenberg, M. Otmar, H. Hrebabecky, et al. 1990. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antivir. Res. 13:295-311.
18. Hukkanen, V., H. Mikola, M. Nykänen, and S. Syrjänen. 1999. Herpes simplex virus type 1 infection has two separate modes of spread in three-dimensional keratinocyte culture. J. Gen. Virol. 80:2149-2155.
19. Junge, R. E., M. C. Duncan, R. E. Miller, D. Gregg, and M. Kombert. 2000. Clinical presentation and antiviral therapy for poxvirus infection in pudu (Pudu puda). J. Zoo Wildl. Med. 31:412-418.
20. Kern, E. R., C. Hartline, E. Harden, K. Keith, N. Rodriguez, J. R. Beadle, and K. Y. Hostetler. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:991-995.
21. Martinez, M. J., M. P. Bray, and J. W. Huggins. 2000. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopox-viral disease in a cowpox virus-BALB/c mouse system. Arch. Pathol. Lab. Med. 124:362-377.
22. Meadows, K. P., S. K. Tyring, A. T. Pavia, and T. M. Rallis. 1997. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch. Dermatol. 133:987-990.
23. Meyers, C., and L.A. Laimins. 1994. In vitro systems for the study and propagation of human papillomaviruses. Curr. Top. Microbiol. Immunol. 186:199-215.
24. Meyers, C., M. Mane, N. Kokorina, S. Alam, and P. L. Hermonat. 2000. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. Virology 272:338-346.
25. Mukinda, V. B., G. Mwema, M. Kilundu, D. L. Heymann, A. S. Khan, and J. J. Esposito. 1997. Re-emergence of human monkeypox in Zaire in 1996. Monkeypox epidemiologic working group. Lancet 349:1449-1450.
26. Nettleton, P. F., J. A. Gilray, H. W. Reid, and A. A. Mercer. 2000. Parapox-viruses are strongly inhibited in vitro by cidofovir. Antivir. Res. 48:205-208.
27. Neyts, J., and E. De Clercq. 1993. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:242-246.
28. Safrin, S., J. Cherrington, and H. S. Jaffe. 1997. Clinical uses of cidofovir. Rev. Med. Virol. 7:145-156.
29. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2000. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir. Chem. Chemother. 11:303-309.
30. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2001. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir. Chem. Chemother. 12:71-76.
31. Smee, D. F., K. W. Bailey, M. H. Wong, and R. W. Sidwell. 2001. Effects of cidofovir on the pathogenesis of a lethal vaccinia respiratory infection in mice. Antivir. Res. 52:55-62.
32. Snoeck, R., L. Lagneaux, A. Delforge, D. Bron, P. Van der Auwera, P. Stryckmans, J. Balzarini, and E. De Clercq. 1990. Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 9:615-619.
33. Syrjänen, S., H. Mikola, M. Nykänen, and V. Hukkanen. 1996. In vitro establishment of lytic and nonproductive infection by herpes simplex virus type 1 in three-dimensional keratinocyte culture. J. Virol. 70:6524-6528.
34. Visalli, R. J., R. J. Courtney, and C. Meyers. 1997. Infection and replication of herpes simplex virus type 1 in an organotypic epithelial culture system. Virology 230:236-243.